Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

被引：5

作者：

Meyers, Brandon M. ^{[1
]}

Knox, Jennifer J. ^{[2
]}

Cosby, Roxanne ^{[3
]}

Beecroft, J. R. ^{[4
]}

Chan, Kelvin K. W. ^{[5
]}

Coburn, Natalie ^{[5
]}

Feld, Jordan J. ^{[6
]}

Jonker, Derek ^{[7
]}

Mahmud, Aamer ^{[8
]}

Ringash, Jolie ^{[9
,10
]}

机构：

[1] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] McMaster Univ, Dept Oncol, Program Evidence Based Care, Hamilton, ON, Canada

[4] Mt Sinai Hosp, Dept Med Imaging, Toronto, ON, Canada

[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[6] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada

[7] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[8] Canc Ctr Southeastern Ontario, Kingston, ON, Canada

[9] Princess Margaret Canc Ctr, Toronto, ON, Canada

[10] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada

来源：

CANADIAN LIVER JOURNAL | 2021年 / 4卷 / 03期

关键词：

hepatocellular carcinoma; non-surgical treatment; systematic review; systemic therapy; tyrosine kinase inhibitor; PHASE-II TRIAL; DOUBLE-BLIND; TRANSARTERIAL CHEMOEMBOLIZATION; PLUS SORAFENIB; OPEN-LABEL; 1ST-LINE THERAPY; 2ND-LINE TREATMENT; MULTICENTER; PLACEBO; HCC;

D O I：

10.3138/canlivj-2020-0039

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND: Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known. METHODS: Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews. RESULTS: Over 30,000 articles were identified. In total, 49 studies were included in the systematic review. CONCLUSIONS: There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.

引用

页码：257 / 274

页数：18

共 56 条

[31] Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [J].

Lee, Francis A. S. ;

Zee, Benny Chung-Ying ;

Cheung, Foon Yiu ;

Kwong, Philip ;

Chiang, Chi Leung ;

Leung, Kwong Chuen ;

Siu, Steven W. K. ;

Lee, Conrad ;

Lai, Maria ;

Kwok, Chloe ;

Chong, Marc ;

Jolivet, Jacques ;

Tung, Steward .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06) :609-613

[32] Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial [J].

Lencioni, Riccardo ;

Llovet, Josep M. ;

Han, Guohong ;

Tak, Won Young ;

Yang, Jiamei ;

Guglielmi, Alfredo ;

Paik, Seung Woon ;

Reig, Maria ;

Kim, Do Young ;

Chau, Gar-Yang ;

Luca, Angelo ;

Ruiz del Arbol, Luis ;

Leberre, Marie-Aude ;

Niu, Woody ;

Nicholson, Kate ;

Meinhardt, Gerold ;

Bruix, Jordi .

JOURNAL OF HEPATOLOGY, 2016, 64 (05) :1090-1098

[33] Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study [J].

Llovet, Josep M. ;

Decaens, Thomas ;

Raoul, Jean-Luc ;

Boucher, Eveline ;

Kudo, Masatoshi ;

Chang, Charissa ;

Kang, Yoon-Koo ;

Assenat, Eric ;

Lim, Ho-Yeong ;

Boige, Valerie ;

Mathurin, Philippe ;

Fartoux, Laetitia ;

Lin, Deng-Yn ;

Bruix, Jordi ;

Poon, Ronnie T. ;

Sherman, Morris ;

Blanc, Jean-Frederic ;

Finn, Richard S. ;

Tak, Won-Young ;

Chao, Yee ;

Ezzeddine, Rana ;

Liu, David ;

Walters, Ian ;

Park, Joong-Won .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3509-+

[34] SELECTIVE INTERNAL RADIATION THERAPY FOR HEPATOCELLULAR CARCINOMA: COMBINATION WITH SORAFENIB IS ASSOCIATED WITH IMPROVED SURVIVAL OUTCOMES [J].

Ma, M. X. ;

Adams, L. ;

Garas, G. ;

Macquillan, G. ;

O'dea, M. ;

Samuelson, S. ;

Tibballs, J. ;

Mac Nicholas, R. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S211-S211

[35]

Maccauro M, 2014, EUR J NUCL MED MOL I, V41, pS291

[36]

Menard A., 2015, FOCAL TUMOUR ABLATIO

[37] Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial [J].

Meyer, Tim ;

Fox, Richard ;

Ma, Yuk Ting ;

Ross, Paul J. ;

James, Martin W. ;

Sturgess, Richard ;

Stubbs, Clive ;

Stocken, Deborah D. ;

Wall, Lucy ;

Watkinson, Anthony ;

Hacking, Nigel ;

Evans, T. R. Jeffry ;

Collins, Peter ;

Hubner, Richard A. ;

Cunningham, David ;

Primrose, John Neil ;

Johnson, Philip J. ;

Palmer, Daniel H. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08) :565-575

[38] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [J].

Palmer, Daniel H. ;

Ma, Yuk Ting ;

Peck-Radosavljevic, Markus ;

Ross, Paul J. ;

Graham, Janet Shirley ;

Fartoux, Laetitia ;

Deptala, Andrzej ;

Wenz, Arne ;

Hocke, Julia ;

Loembe, Arsene-Bienvenu ;

Meyer, Tim .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

[39] Sorafenib with versus without concurrent conventional transarterial chemoembolization (cTACE) in patients with advanced hepatocellular carcinoma (HCC): Results from a multicenter, open-label, randomized, controlled phase III STAH trial [J].

Park, J. -W. ;

Kim, Y. J. ;

Kim, D. Y. ;

Bae, S. H. ;

Paik, S. W. ;

Lee, Y. -J. ;

Lee, D. ;

Lee, H. C. ;

Han, S. Y. ;

Cheong, J. Y. ;

Kwon, O. S. ;

Yeon, J. E. ;

Kim, B. H. ;

Hwang, J. -S. .

JOURNAL OF HEPATOLOGY, 2018, 68 :S2-S2

[40] Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study [J].

Rimassa, Lorenza ;

Assenat, Eric ;

Peck-Radosavljevic, Markus ;

Pracht, Marc ;

Zagonel, Vittorina ;

Mathurin, Philippe ;

Caremoli, Elena Rota ;

Porta, Camillo ;

Daniele, Bruno ;

Bolondi, Luigi ;

Mazzaferro, Vincenzo ;

Harris, William ;

Damjanov, Nevena ;

Pastorelli, Davide ;

Reig, Maria ;

Knox, Jennifer ;

Negri, Francesca ;

Trojan, Jorg ;

Lopez, Carlos Lopez ;

Personeni, Nicola ;

Decaens, Thomas ;

Dupuy, Marie ;

Sieghart, Wolfgang ;

Abbadessa, Giovanni ;

Schwartz, Brian ;

Lamar, Maria ;

Goldberg, Terri ;

Shuster, Dale ;

Santoro, Armando ;

Bruix, Jordi .

LANCET ONCOLOGY, 2018, 19 (05) :682-693

← 1 2 3 4 5 6 →